- Halozyme Therapeutics (HALO -3.9%) slips after being downgraded to EqualWeight at Barclays.
- The firm cites concern over FDA approval for certain product lines, saying it believes that PH20 remains a commercially viable platform, but FDA concerns over antibodies to PH20 put a damper on the approvability of any blood product such as HyQ and Cinryze in combination with PH20.
- Barclays thinks the overhang will likely limit the stock's upside potential - especially in light of the VPHM announcement.
From other sites
at 4-traders.com (Mar 23, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 9, 2015)
at Benzinga.com (Jan 8, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs